Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236066 | 0.81 | MAOB (0.46) | MAOBCA2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL9391114 | 0.81 | MAOB (0.53) | MAOBCA2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL5240880 | 0.79 | MAOB (0.44) | MAOBCA2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL3670952 | 0.79 | KDM1A (0.36) | MAOBIL4I1 | |
| SCHEMBL31426148 | 0.76 | EED (0.43) | MAOBMAOA | |
| SCHEMBL6511946 | 0.75 | MAOB (0.71) | MAOBCA2CYP17A1CYP19A1CYP11B1 | |
| SCHEMBL2224710 | 0.75 | SMN1; SMN2 (0.36) | CYP19A1 | |
| SCHEMBL15897810 | 0.75 | CSNK2A1 (0.46) | CYP19A1KCNH2 | |
| SCHEMBL8950321 | 0.75 | CSNK2A1 (0.50) | KCNH2 | |
| SCHEMBL6613340 | 0.75 | PTPN1 (0.43) | CYP17A1CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469741-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2016-10-18 | — | — | US | claimed |
| EP-2203482-B1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORP (JP) | 2015-11-25 | — | — | EP | claimed |
| US-20150267031-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2015-09-24 | — | — | US | claimed |
| US-9085646-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2015-07-21 | — | — | US | claimed |
| US-20130066016-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2013-03-14 | — | — | US | claimed |
| US-8362156-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2013-01-29 | — | — | US | claimed |
| US-8314189-B2 | Polymers functionalized with heterocyclic nitrile compounds | BRIDGESTONE CORPORATION (JP) | 2012-11-20 | — | — | US | claimed |
| US-20100280217-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2010-11-04 | — | — | US | claimed |
| US-20090099325-A1 | POLYMERS FUNCTIONALIZED WITH HETEROCYCLIC NITRILE COMPOUNDS | BRIDGESTONE CORPORATION | 2009-04-16 | — | — | US | claimed |
| WO-2026102105-A1 | FUNCTIONAL POLYBUTADIENE AND CARBON BLACK IN RUBBER COMPOUNDS | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20250346583-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | disclosed |
| EP-4532012-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023227696-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-11512148-B2 | Composition including multiple terminally functionalized polymers | BRIDGESTONE CORPORATION (JP) | 2022-11-29 | — | — | US | disclosed |
| EP-0214556-A1 | Substituted hexahydro-arylquinolizine derivatives, processes for their preparation and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1987-03-18 | — | — | EP | disclosed |
| EP-0204254-A2 | Substituted hexahydro arylquinolizines, processes for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-12-10 | — | — | EP | disclosed |
| EP-0154142-A1 | Substituted hexahydro arylquinolizines | MERCK & CO. INC. (US) | 1985-09-11 | — | — | EP | disclosed |
| EP-0009780-B1 | OCTAHYDRO-1H-BENZO(4,5)FURO(3,2-E)ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| EP-0020391-A1 | SUBSTITUTED ACETIC ACID ESTERS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1981-01-07 | — | — | EP | disclosed |
| WO-1980000563-A1 | SUBSTITUTED ACETIC ACID ESTERS | SOREX LTD (GB) | 1980-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346583-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM2, TRPM6 | MAOB 2260/4885CA2 441/4885CYP17A1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.